This pharmaceutical stock is cheap relative to peers. UBS thinks it's due for a bounce
The investment bank upgraded the pharmaceutical name to buy from neutral.
ORIGINAL SOURCE →via CNBC Top News
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · finance
- [FINANCE] The Role of Cloud-Native Infrastructure in Payments Modernization
- [FINANCE] How to Create a Customer Persona for Your Startup (2026)
- [FINANCE] CME (CME) Q2 2025 Earnings Call Transcript - The Motley Fool
- [FINANCE] US Treasury Secretary says renewing sanctions relief on Iranian, Russian oil for another 30 days - The Times of Israel
- [FINANCE] US treasury to extend sanctions relief on Russian and Iranian oil
- [FINANCE] Why Intel’s stock still offers compelling value — even after this year’s 80% gain